Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas

Jun Gong1,*
Jessica Yan2,*
Charles Forscher3
Andrew Hendifar4

1Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA; 2Department of Hematology and Oncology, Harbor-UCLA Medical Center, Torrance, CA, USA; 3Sarcoma Program, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA; 4Gastrointestinal and Neuroendocrine Malignancies, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA

*These authors contributed equally to this work

Abstract: Despite available therapies after initial systemic therapy, prognosis remains poor in relapsed or refractory soft tissue sarcomas (STS). The rational and clinical development of novel agents to improve outcomes in this area of high unmet need is desperately warranted. Aldoxorubicin is a prodrug of doxorubicin that binds to serum albumin immediately after administration through an acid-sensitive hydrazide linker and is subsequently transported to tumor tissues where the acidic environment cleaves the linker and facilitates delivery of a tumor-targeted drug payload. In clinical studies to date, there has been evidence of efficacy and mitigated cardiac toxicity. In this review, we comprehensively detail the clinical development of aldoxorubicin in STS to date. Specifically, we highlight available data on the pharmacokinetics and efficacy from Phase I, Phase II, and Phase III trials in advanced or metastatic STS. We conclude with considerations for future directions of investigation for this promising antitumor agent.

Keywords: aldoxorubicin, albumin conjugate, soft tissue sarcomas, clinical trials, pharmacokinetics, cardiotoxicity

Introduction

Soft tissue sarcomas (STS) comprised a biologically heterogeneous group of malignancies with >50 subtypes.1 Collectively, STS are relatively rare and account for <1% of adult cancers with an estimated 12,390 new cases in the USA in 2017.2 Approximately 50% of patients with high-grade STS develop metastatic diseases, and the median overall survival (OS) for advanced or metastatic STS has ranged from 12 months (historical) to 18–19 months (contemporary).1 For a select group of sarcomas including gastrointestinal stromal tumors (GISTs), innovative and histology-specific targeted therapies are available.3–12 However, for the majority of advanced STS, of which the most common high-grade subtypes include undifferentiated pleomorphic sarcoma (UPS), liposarcoma (LPS), leiomyosarcoma (LMS), synovial sarcoma (SS), and malignant peripheral nerve sheath tumors (MPNSTs), anthracycline (eg, doxorubicin)-based systemic therapy remains the standard first-line therapy.1

Dose-intensive combination chemotherapy with doxorubicin and ifosfamide (AI) with granulocyte colony-stimulating factor (GCSF) support is a currently favored approach in the initial or first-line treatment of advanced or unresectable STS in patients with good performance status (PS) and particularly when there is a need to relieve acute symptoms or for tumor debulking prior to surgery or radiation therapy.13–16 Although no OS benefit was demonstrated between first-line doxorubicin and AI in a Phase III randomized trial, several factors could have affected the lack of an OS difference.13
The study required enrollment of patients having confirmed unresectable or metastatic disease progression within 6 weeks of treatment that may have excluded a number of patients with high-grade STS that would have potentially benefited from combination therapy. The first randomization occurred in 2003, and survival analysis for this trial was still ongoing at the time of publication in 2014. The effect of postprotocol treatment on survival was not assessed but potentially could have impacted OS in both cohorts.13 Nevertheless, recommendations for AI in this population have been supported based on significantly improved progression-free survival (PFS) and overall response rates (ORRs) with combination therapy, though often at the expense of increased adverse events (AEs), when compared with control arms.13–16 More recently, the combination of doxorubicin and olaratumab (anti-platelet-derived growth factor receptor [PDGFR] antibody) was approved by the US Food and Drug Administration (FDA) for anthracycline-naive locally advanced, unresectable, or metastatic STS and represents another option in the front-line setting that should be considered in those with good PS.17

In patients with unresectable or metastatic STS who are less fit and for whom therapy is palliative to control metastatic diseases, sequential single-agent chemotherapy with doxorubicin, ifosfamide, or liposomal doxorubicin (Doxil®) is often recommended, given the likely lower toxicity without significant impairment in survival associated with this approach.11–18 Significant improvements in outcomes (ORR, PFS, and OS) are still seen in previously treated patients with advanced or unresectable STS and good PS; in particular, clinical benefit was seen when modern therapies (single-agent or combination therapies developed during the trabectedin era) were compared with older, conventional agents or best supportive care after failure of first-line therapies.21 In the modern era, therapies after first-line treatment are increasingly being tailored to histologic and molecular subtypes of advanced STS including high-dose ifosfamide in SS,22,23 gemcitabine and docetaxel in UPS or LMS (particularly uterine LMS),24–27 trabectedin in LMS or LPS (particularly myxoid/round cell LPS),28 pazopanib in all STS subtypes except LPS,29 and eribulin in LPS.30

Although doxorubicin is an effective therapy in sarcoma, its dose-dependent risk of cardiotoxicity seen with cumulative doses 300–950 mg/m² remains a significant safety concern. Consequently, continuous use or rechallenge with doxorubicin is limited by the finite number of cycles that can be administered safely in the treatment course for advanced STS. Furthermore, despite the availability of therapies for STS when standard treatments have failed (salvage therapies), prognosis remains poor in relapsed or refractory STS patients with a median OS of 8–12 months.21 The rational and clinical development of novel agents to improve outcomes in this area of high unmet need is desperately warranted. In this review, we highlight the clinical development of aldoxorubicin, a doxorubicin derivative with promising activity in the treatment of advanced STS. In particular, the pharmacokinetics (PKs), toxicity profile, and results thus far available from Phase I–III trials of aldoxorubicin in advanced STS are reviewed.

**Mechanism of action**

Aldoxorubicin is a prodrug of doxorubicin with acid-sensitive properties that binds covalently to serum albumin in the bloodstream and accumulates in tumors.31–33 Endogenous albumin is a potential drug carrier because it accumulates in solid tumors due to the high cell turnover, angiogenic, defective vascular architecture, and impaired lymphatic drainage characteristic of tumor tissues.32 Furthermore, the HS group of Cys34 of albumin is absent in the majority of remaining circulating serum proteins, making it an accessible functional group.33,35 Selective binding of thiol-reactive prodrugs to the Cys34 position of endogenous albumin occurring after intravenous administration that is followed by the release of the albumin-bound drug at the tumor site represents the macromolecular prodrg strategy of aldoxorubicin.31 Aldoxorubicin contains an acid-sensitive hydrazone linker that facilitates doxorubicin release either intracellularly in acidic lysosomal (or endosomal) compartments after cellular uptake of the albumin conjugate by tumor cells or extracellularly in the slightly acidic environment often present in tumor tissues.33

**PKs**

An early Phase I study characterized the PKs of aldoxorubicin (DOXO-EMCH or INNO-206) in 41 patients with treatment-refractory advanced solid tumors administered aldoxorubicin 20–340 mg/m² as intravenous (IV) 30 min infusions during the first cycle of therapy (every 3 week cycles).35 The mean half-lives (t₁/₂) of DOXO-EMCH ranged from 17.6 to 38.2 h and were in the same order as the t₁/₂ reported for doxorubicin (~15–40 h). The mean peak concentrations (Cₘₐₓ) after administration of DOXO-EMCH ranged from 11.3 to 234.6 μmol/L, and the mean area under concentration/time curve up to the last quantifiable concentration (AUC₀ₙ) ranged from 169.6 to 2,547 h μmol/L with the large AUC values representing the long circulating drug delivery system and
the stability of DOXO-EMCH in circulation. Reported AUC values for conventional doxorubicin have been ~3 h μmol/L for a dose of 60 mg/m². There was a dose-dependent relationship between dose of DOXO-EMCH administered and $C_{\text{max}}$ and AUC$_{\text{all}}$ (except for the 150 and 180 mg/m² dose groups). The mean total body clearance of doxorubicin (Cl$_{\text{obs}}$) ranged from 2.15 to 3.37 mL/min/m², which is significantly lower than that of conventional doxorubicin (~580 mL/min/m²). There was no relationship between Cl and dose of DOXO-EMCH. The volume of distribution ($F_{\text{v}}$) was narrow (3.96–4.08 L/m²) and suggests an inability of aldoxorubicin to readily accumulate in third spaces.

A later Phase I trial evaluated the PKs of a new formulation of aldoxorubicin with improved reconstitution and reduced or eliminated inactive ingredients administered as 230 or 350 mg/m² 30 min infusions during cycle 1 (21-day cycles) in 18 patients with relapsed or refractory advanced solid tumors. Here, aldoxorubicin demonstrated a mean circulating $t_{1/2}$ of 20.1–21.1 h, a narrow mean $V_{\text{d}}$ of 3.96–4.09 L/m², and a slow mean Cl of 0.136–0.152 L/h/m². The mean $C_{\text{max}}$ ranged from 67,400 to 105,000 ng/mL, and only a small fraction of the plasma concentration comprised free doxorubicin and doxorubicinol (4.17–13.7 ng/mL), which suggests that almost all doxorubicin in the circulation remains bound to albumin via the acid-sensitive linker. These features suggest that aldoxorubicin is stable in circulation and is not released until exposed to an acidic environment such as that found at the tumor site. Furthermore, only trace amounts of doxorubicinol, the major metabolite of doxorubicin implicated in doxorubicin-associated cardiomyopathy, was found excreted in urine and may account for the minimal cardiotoxicity observed with aldoxorubicin treatment.

**Phase I trials**

There have been six Phase I trials of aldoxorubicin conducted thus far to characterize the toxicity profile, maximum tolerated dose (MTD), and preliminary efficacy (Table 1). In one Phase I trial of aldoxorubicin administered as 230 or 350 mg/m² 30 min infusions on day 1 of every 21-day cycle in 18 patients with relapsed or refractory advanced solid tumors, there were 11/22 (50.0%) possibly or definitely treatment-related grades 3–4 AEs with one aldoxorubicin-related serious AE of febrile neutropenia (did not receive GCSF). There were three partial responses (PRs): one with thyroid cancer in the 230 mg/m² group who had nine cycles completed, one with mesothelioma in the 350 mg/m² group, and one with small-cell lung cancer (SCLC) with an unconfirmed PR after four cycles in the 230 mg/m² group.

**Table 1 Phase I clinical trials of aldoxorubicin**

<table>
<thead>
<tr>
<th>n</th>
<th>Design</th>
<th>Tumor histology</th>
<th>Doses</th>
<th>Primary endpoint</th>
<th>Results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>18</td>
<td>Open label, single-center, single arm</td>
<td>Various relapsed or refractory advanced solid tumors</td>
<td>230 or 350 mg/m² IV 30 min infusion on day 1 every 21 days</td>
<td>PKs</td>
<td>$t_{1/2}$: 20.1–21.1 h &lt;br&gt;Mean $V_{d}$: 3.96–4.08 L/m² &lt;br&gt;Mean Cl: 0.136–0.152 L/h/m²</td>
<td>32</td>
</tr>
<tr>
<td>41</td>
<td>Open label, single-center, single arm</td>
<td>Various relapsed or refractory advanced solid tumors</td>
<td>20–340 mg/m² IV 30 min infusion on day 1 every 21 days</td>
<td>MTD</td>
<td>MTD: 340 mg/m² (RP2D 260 mg/m²) &lt;br&gt;DLT: myelosuppression (grades 1–3) and mucositis (grades 1–3)</td>
<td>33</td>
</tr>
<tr>
<td>25</td>
<td>Open label, single-center, single arm</td>
<td>Various relapsed or refractory advanced solid tumors</td>
<td>230, 350, or 450 mg/m² IV 30 min infusion on day 1 every 21 days</td>
<td>MTD</td>
<td>MTD: 350 mg/m² &lt;br&gt;DLT: neutropenia (grade 4) and febrile neutropenia (grade 3)</td>
<td>34</td>
</tr>
<tr>
<td>27</td>
<td>Open label, single-center, single arm</td>
<td>Previously treated or untreated advanced STS</td>
<td>250 mg/m² IV on day 1 with continuous infusion of I–M days 1–14 every 28 days</td>
<td>Efficacy Toxicity</td>
<td>42% PR, 58% SD, median PFS not reached &lt;br&gt;Toxicities (grades 3–4): neutropenia (78%), anemia (65%), thrombocytopenia (22%), febrile neutropenia (9%), no decrease in LVEF &gt;20% doxorubicin</td>
<td>35</td>
</tr>
<tr>
<td>10</td>
<td>Open label, single-center, single arm</td>
<td>Various relapsed or refractory advanced solid tumors</td>
<td>175, 240, or 320 mg/m² plus doxorubicin 35 mg/m² IV both on day 1 every 21 days</td>
<td>MTD</td>
<td>MTD: 320 mg/m² aldoxorubicin and 35 mg/m² doxorubicin &lt;br&gt;No DLT observed</td>
<td>36</td>
</tr>
<tr>
<td>22</td>
<td>Open label, multicenter, single arm</td>
<td>Various relapsed or refractory advanced solid tumors</td>
<td>A 170 mg/m² + G 900 mg/m²; A 250 mg/m² + G 900 mg/m²; A 200 mg/m² + G 750 mg/m² (A on day 1 and G on days 1–8, every 21 days)</td>
<td>RP2D</td>
<td>RP2D: A 200 mg/m² + G 500 mg/m² &lt;br&gt;DLT: thrombocytopenia (grades 3–4)</td>
<td>37</td>
</tr>
</tbody>
</table>

**Abbreviations:** A, aldoxorubicin; Cl, clearance rate; DLT, dose-limiting toxicity; G, gemcitabine; I–M, ifosfamide/mesna; IV, intravenous; LVEF, left ventricular ejection fraction; MTD, maximum tolerated dose; PFS, progression-free survival; PKs, pharmacokinetics; PR, partial response; RP2D, recommended phase II dose; SD, stable disease; STS, soft tissue sarcoma; $t_{1/2}$, half-life; $V_{d}$, volume of distribution.
There were three patients with stable disease (SD) and tumor shrinkage. PKs was the primary endpoint of this study and was previously described (Table 1). An earlier open-label, dose-escalation, Phase I study administered aldoxorubicin (DOXO-EMCH) in 41 patients with treatment-refractory advanced solid tumors at 20–340 mg/m² as 30-min infusions on day 1 of every 21-day cycle to determine the MTD and dose-limiting toxicities (DLTs).33 No DLTs were observed until up to the 200 mg/m² dose level where one grade 4 neutropenia occurred resulting in expansion to six patients. The MTD was defined as 340 mg/m² where DLTs of myelosuppression and myelosuppression occurred, while the recommended phase II dose (RP2D) was 260 mg/m². At 260 mg/m², grades 1–2 myelosuppression and grades 1–2 mucositis were the most frequent AEs. Of the 30 evaluable patients, there were three patients with PRs (180–340 mg/m²) and 15 patients with SD.

A Phase Ib, open-label study of new formulation aldoxorubicin administered at 230, 350, or 450 mg/m² on day 1 every 21 days determined that aldoxorubicin at a dose of 350 mg/m² every 21 days for up to eight cycles was safe and demonstrated preliminary efficacy.34 A total of 25 patients with relapsed or refractory advanced solid tumors were enrolled, and at the 450 mg/m² dose level, two patients with DLTs of grade 4 neutropenia and grade 3 febrile neutropenia were enrolled and 350 mg/m² was defined as the MTD (Table 1). At the MTD, the most common grades 3–4 AE was myelosuppression with two events of febrile neutropenia (11%) and six patients discontinued treatment due to treatment-related AEs. No patients experienced a decrease in left ventricular ejection fraction (LVEF) to <45% of predicted. The ORR of the overall cohort was 20% (five PRs), and the median PFS was 4.80 months (95% confidence interval [CI] 2.63–13.85) with 10 patients who experienced SD (40%). Of the 13 patients with STS at the MTD, there were five PRs (38%) and six patients with SD (46%) with a median PFS of 11.25 months (95% CI 4.80–21.71).

A separate open-label, Phase I study demonstrated that aldoxorubicin can also be administered safely with other chemotherapy agents commonly used in the treatment of STS.35 Here, aldoxorubicin administered at 250 mg/m² on day 1 with continuous infusion of ifosfamide and mesna (1 g/m² each per day up to 14 days for a maximum of 6 28-day cycles) in 27 patients with STS in the first- or second-line settings showed promising ORR with the most common AE being myelosuppression (Table 1). There were 10 patients with PR or SD who had subsequent surgery to remove accessible tumors. One open-label, dose-escalation, Phase Ib study investigated IV aldoxorubicin administered at 175, 240, or 320 mg/m² with 35 mg/m² IV doxorubicin both on day 1 of 21-day cycles (for up to eight cycles) to determine the MTD of this combination.36 Aldoxorubicin (320 mg/m²) can be safely administered with doxorubicin (35 mg/m²) without adding further toxicity as no DLTs occurred in 10 patients with STS. No significant mucositis or cardiotoxicity was observed, but grades 3–4 AEs occurred in 8/10 patients with neutropenia, 4/10 patients with thrombocytopenia, 3/10 patients with anemia, and 3/10 patients with febrile neutropenia. Although hematologic toxicity was common, it can be controlled with growth factors. The best response at the time of this study was SD in 6/10 patients and one PR in a patient with malignant fibrous histiocytoma (MFH).

Finally, a Phase Ib study showed that aldoxorubicin can be administered safely at a RP2D of IV 200 mg/m² (on day 1) with gemcitabine 500 mg/m² (on days 1–8) over 21-day cycles.37 Of the 22 patients with relapsed or refractory solid tumors, thrombocytopenia was the major grades 3–4 AE that was dose limiting, though 11 serious AEs were observed including Klebsiella infection, sepsis, febrile neutropenia, thrombocytopenia, anemia, stomatitis, small bowel obstruction, fever, pneumonia, pleural effusion, and urinary tract infection. Cardiac function was monitored by echocardiogram every 2 months, and no significant cardiotoxicity was observed. There were two patients with PRs (uterine LMS and ovarian cancer) and 11 patients with SD as best responses so far.

**Phase II trials**

In an international, multicenter, open-label, Phase Ib trial randomizing (2:1) patients with locally advanced, unresectable, and/or metastatic STS to receive first-line IV aldoxorubicin 350 mg/m² or doxorubicin 75 mg/m² every 21 days (up to six cycles), the primary endpoint of PFS was significantly improved with aldoxorubicin compared to doxorubicin with a 6-month PFS rate of 46 vs 23% (P=0.02, Table 2).38 The median OS was 15.8 months (95% CI 13.0–not available) with aldoxorubicin and 14.3 months (95% CI 8.6–20.6, hazard ratio [HR] 0.73, 95% CI 0.44–1.20, P=0.21) with doxorubicin, though this study was not powered for OS. ORRs were also higher with aldoxorubicin compared to doxorubicin (25 vs 0%). Grades 3–4 neutropenia was more frequent with aldoxorubicin than with doxorubicin (29 vs 12%), but not grades 3–4 febrile neutropenia (14 vs 18%). Treatment discontinuation due to AEs occurred in 6% in the aldoxorubicin group and 8% in the doxorubicin group. Notably, three patients in the doxorubicin group...
Drug Design, Development and Therapy 2018:12

submit your manuscript | www.dovepress.com

Dovepress

Aldoxorubicin for relapsed or refractory sarcomas

Table 2 Phase II clinical trials of aldoxorubicin in advanced or metastatic STS

<table>
<thead>
<tr>
<th>n</th>
<th>Design</th>
<th>Experimental arm</th>
<th>Control arm</th>
<th>Primary endpoint</th>
<th>Results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>126 patients</td>
<td>Randomized, open label,</td>
<td>Aldoxorubicin</td>
<td>Doxorubicin</td>
<td>Median PFS</td>
<td>Median PFS 5.6 months (95% CI 3.0–8.1) vs 2.7 months (95% CI 1.6–4.3, P=0.02)</td>
<td>38</td>
</tr>
<tr>
<td>with various</td>
<td>multicerter</td>
<td>350 mg/m² IV</td>
<td>75 mg/m² IV every 21 days</td>
<td></td>
<td>Secondary endpoints: 6-month PFS rate (46 vs 23%, P=0.02); median OS 15.8 months (95% CI 13.0–NR) vs 14.3 months (95% CI 8.6–20.6, P=0.21); ORR 25% vs 0%</td>
<td></td>
</tr>
<tr>
<td>advanced STS,</td>
<td></td>
<td>every 21 days</td>
<td>every 21 days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>first line</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nine patients</td>
<td>Randomized, open label,</td>
<td>Aldoxorubicin</td>
<td>None</td>
<td>Safety Efficacy</td>
<td>1/9 patients with grade 4 neutropenia at 100 mg/m²</td>
<td>39</td>
</tr>
<tr>
<td>with AIDS-related</td>
<td>multicerter</td>
<td>50, 100, or 150 mg/m² IV</td>
<td></td>
<td></td>
<td>4/6 patients responded</td>
<td></td>
</tr>
<tr>
<td>related KS,</td>
<td></td>
<td>every 21 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>first line</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>and second line</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; IV, intravenous; KS, Kaposi sarcoma; KSHV, KS herpes virus; NR, not reported; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; STS, soft tissue sarcomas.

Phase III trials

In a pivotal international, multicenter, Phase III trial evaluating PFS as the primary endpoint, 433 patients with relapsed or refractory STS were randomly assigned to receive IV aldoxorubicin 350 mg/m² (260 mg/m² doxorubicin equivalent) every 3 weeks or investigator’s choice of treatment (IC) including dacarbazine, doxorubicin, pazopanib, ifosfamide, and gemcitabine/docetaxel with GCSE support. Tumor subtypes included LMS (42.2%), LPS (12.8%), SS (9.6%), and other sarcomas (34.9%). Approximately two-thirds of the patients received prior doxorubicin in both experimental and control arms. The mean cumulative doxorubicin equivalent dose of aldoxorubicin administered was 1,359.8 mg/m² (range 260–10,920). Aldoxorubicin demonstrated superior median PFS over IC in patients with LMS or LPS (L-sarcomas) and in patients enrolled in North America (Table 3). In the overall cohort, median PFS was not significantly different between aldoxorubicin and IC arms. Secondary endpoints included ORR, disease control rate (DCR), OS, and safety. Although the ORR was twice as high in the aldoxorubicin arm (8.3 vs 4.2%, P=0.1106), there was no significant difference in median OS (12.88 months, 95% CI 10.05–15.11 vs

Table 3 Phase III clinical trial of aldoxorubicin in advanced or metastastic STS

<table>
<thead>
<tr>
<th>n</th>
<th>Design</th>
<th>Experimental arm</th>
<th>Control arm</th>
<th>Primary endpoint</th>
<th>Results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>433 patients</td>
<td>Randomized, open label,</td>
<td>Aldoxorubicin</td>
<td>IC</td>
<td>PFS</td>
<td>Median PFS (overall): A 4.11 months (95% CI 2.79–5.06) vs IC 2.96 months (95% CI 2.56–4.16); HR 0.81 (95% CI 0.64–1.03, P=0.087)</td>
<td>40</td>
</tr>
<tr>
<td>with various</td>
<td>multicerter</td>
<td>350 mg/m² IV</td>
<td>every 21 days</td>
<td></td>
<td>Median PFS (NA): A 4.21 months (95% CI 2.92–6.21) vs IC 2.96 months (95% CI 2.76–4.07); HR 0.71 (95% CI 0.53–0.96, P=0.0225)</td>
<td></td>
</tr>
<tr>
<td>advanced STS,</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Median PFS L-sarcomas: A 5.32 months (95% CI 3.45–7.16) vs IC 2.96 months (95% CI 2.10–4.37); HR 0.62 (95% CI 0.44–0.88, P=0.007)</td>
<td></td>
</tr>
<tr>
<td>second-line</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Secondary endpoints: ORR 8.3 vs 4.2% (P=0.1106); median OS 12.88 months (95% CI 10.05–15.11) vs 12.16 months (95% CI 10.38–13.31, P=0.8555)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: A, aldoxorubicin; CI, confidence interval; HR, hazard ratio; IC, investigator’s choice of treatment; NA, North America; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; STS, soft tissue sarcomas; L-sarcoma, liposarcoma or leiomyosarcoma.
12.16 months, 95% CI 10.38–13.31, \( P = 0.8555 \)). There was a trend toward significantly improved ORR in the L-sarcomas cohort treated with aldoxorubicin (10.0 vs 4.0%, \( P = 0.0790 \)) compared to IC. In the intent-to-treat population, the DCR was 33.5% with aldoxorubicin vs 25.1% with IC (\( P = 0.0583 \)). This achieved statistical significance in patients with L-sarcomas (41.7 vs 27.0%, \( P = 0.0161 \)). Of the 213 patients randomized to aldoxorubicin and 207 patients randomized to IC, treatment-related AEs leading to study drug discontinuation was observed in 8.9 and 6.8%, respectively. There were more grade \( \geq 3 \) AEs (74.2 vs 64.3%), grade \( \geq 3 \) treatment-related AEs (64.3 vs 46.9%), serious AEs (42.7 vs 32.9%), and treatment-related AEs resulting in death (1.4 vs 0%) in the aldoxorubicin arm. The most common grade \( \geq 3 \) AEs (\( \geq 5\% \)) were neutropenia (23.9%), anemia (22.1%), febrile neutropenia (15.5%), and stomatitis (15.5%) in the aldoxorubicin arm and anemia (13.5%), neutropenia (11.6%), and thrombocytopenia in the IC arm. Cardiac toxicity, defined by \( > 20\% \) decrease in LVEF, was lower in patients receiving aldoxorubicin compared to those in the IC arm receiving doxorubicin (3.8 vs 8.5%). There were fewer patients with LVEF <50% of any postbaseline visit in the aldoxorubicin arm as well (4.2 vs 19.1%). Interestingly, no alopecia was noted in the aldoxorubicin group. In summary, aldoxorubicin was associated with a superior PFS compared with standard of care (SOC) regimens in North America and L-sarcomas suggesting that it may be the superior anthracycline compared to doxorubicin in advanced STS. Furthermore, aldoxorubicin represents a viable alternative compared to SOC in patients with relapsed or refractory metastatic STS.

**Discussion**

Salvage therapies in advanced or metastatic STS after initial or first-line treatment have been shown to confer an absolute benefit in OS and PFS by 3.3 and 1.6 months, respectively, and a near doubling of ORR when compared with control.\(^{21}\) Furthermore, survival after failure of first-line therapy accounts for \( > 70\% \) of the entire OS despite postprogression therapies and crossover to other agents that may potentially dilute the absolute gain – altogether highlighting the activity of new agents even in treatment-refractory STS.\(^{21}\) However, despite these advances in therapies after initial treatment of advanced STS, prognosis remains dismal with a median OS of 8–12 months.\(^{21}\) To this end, aldoxorubicin shows promise in fulfilling an unmet need for effective treatments in relapsed or refractory advanced STS.\(^{41}\)

Aldoxorubicin has shown activity in first-line and beyond settings in advanced STS with the most common DLT being myelosuppression that can be reasonably controlled with GCSF support (Tables 1–3). Its PKs is characterized by a slow Cl and narrow \( V_{m} \) supporting its low tendency to accumulate in third spaces and an albumin conjugate tumor targeting design that ensures its stability in the circulation where almost all doxorubicin remains bound to albumin until exposed to the acidic environment of tumor tissues. Furthermore, only trace amounts of doxorubicinol, the major metabolite of doxorubicin implicated in doxorubicin-associated cardiomyopathy, are found excreted in urine and may account for the minimal cardiotoxicity observed with aldoxorubicin treatment.\(^{32,33}\)

In the largest study to date that demonstrated superior PFS with aldoxorubicin over doxorubicin in the first-line treatment of advanced STS, aldoxorubicin produced a median PFS of 5.6 months (95% CI 3.0–8.1), OS of 15.8 months (95% CI 13.0–not reached), and ORR of 25%.\(^{38}\) Notably, OS was not significantly different between aldoxorubicin and doxorubicin, though this study was not powered for OS.\(^{38}\) As a comparison to historical standard first-line therapies, the combination of doxorubicin and ifosfamide produced a median PFS range of 7.3–7.4 months, OS range of 13.8–14.3 months, and ORR range of 23.3–26% across two large, randomized Phase III studies in advanced STS.\(^{13,14}\)

In the Phase Ib/II trial that led to the approval of doxorubicin and olaratumab in the first-line treatment of advanced STS, the combination resulted in a median PFS of 6.6 months (95% CI 4.1–8.3), OS of 26.5 months (95% CI 20.9–31.7), and ORR of 18.2% (95% CI 9.8–29.6).\(^{17}\) The median PFS and ORR observed with aldoxorubicin are comparable to those observed with doxorubicin/ifosfamide and doxorubicin/olaratumab in the first-line treatment of advanced STS.\(^{13,17,38}\) The median OS with aldoxorubicin is comparable with that of doxorubicin and ifosfamide but lower than the median OS seen in the doxorubicin and olaratumab study.\(^{13,14,17,38}\) Great caution should be taken in these historical comparisons, however, as differences in study design, patient characteristics, and disease biology can significantly influence the interpretability of such cross-study comparisons. For example, the median PFS (2.7 months, 95% CI 1.6–4.3) and the median ORR (0%) in the doxorubicin control arm of the aldoxorubicin study are lower than those in the doxorubicin control arms of the doxorubicin/olaratumab (median PFS 4.1 months, 95% CI 2.8–5.4; ORR 11.9%) and doxorubicin/ifosfamide (median PFS 4.6 months, 95% CI 2.9–5.6; ORR 14%) studies that suggest the presence of heterogeneity across study populations.\(^{13,17,38}\) Ultimately, the comparison of the efficacy of aldoxorubicin with current standards in
the first-line treatment of advanced STS would be best served in the setting of a large, randomized, and adequately powered prospective study. There are currently no ongoing clinical trials investigating such comparisons, but studies of this nature are certainly warranted to elucidate the role of aldoxorubicin in the first-line treatment of unresectable or metastatic STS.

In the relapsed or refractory setting, the efficacy of aldoxorubicin was directly compared with standard therapies including dacarbazine, doxorubicin, pazopanib, ifosfamide, and gemcitabine/docetaxel in patients with previously treated advanced STS. In this pivotal Phase III trial, aldoxorubicin showed superior PFS to IC in relapsed or refractory advanced STS in prespecified analyses of the North American (vs European Union) and L-sarcoma (vs other sarcomas) cohorts.\textsuperscript{40} Notably, a majority of 68.4% of patients were enrolled into the North American cohort and the distribution of L-sarcomas in this cohort was not reported. Heterogeneity in sarcoma subtypes across cohorts may, in part, explain the geographical differences observed in PFS seen with aldoxorubicin compared to doxorubicin. The lack of OS difference in this trial compared to IC in the overall cohort is unclear, and final mature OS results are eagerly awaited as well as commentary on degree of patient cross-over.

Aldoxorubicin has also shown superior safety with respect to cardiotoxicity in animals and humans.\textsuperscript{32,33,42} Although doxorubicin is an effective treatment in sarcoma, its benefits are often limited by the dose-dependent risk of cardiotoxicity. This risk of cardiotoxicity has been shown to be attributable to the metabolism of doxorubicin to doxorubicinol and its effects on cardiac tissue.\textsuperscript{43,44} Very low levels of the metabolite doxorubicinol are excreted in the urine following aldoxorubicin administration, perhaps explaining the lack of cardiotoxicity associated with aldoxorubicin.\textsuperscript{32} When DOXO-EMCH (aldoxorubicin) is administered in rats at doses of 1.1 and 3.3 mg/kg compared to doxorubicin (0.8 mg/kg weekly for 7 weeks), both DOXO-EMCH groups did not differ from controls that received saline in regard to clinical symptomatology, mortality, and mitochondrial enzymes associated with cardiomyopathy. The doxorubicin-exposed rats, however, had severe clinical and histopathological cardiomyopathies with associated parameters correlated with myocardial damage.\textsuperscript{42} As a result, several fold higher doses of aldoxorubicin can be administered with cumulative doses (>2,000 mg/m\textsuperscript{2}) of doxorubicin equivalents and have been achieved without the associated cardiotoxicity typically seen with cumulative doxorubicin doses 300–950 mg/m\textsuperscript{2}.\textsuperscript{34,38}

The long-term cardiac safety profile of aldoxorubicin has been shown by reviewing data from three Phase I studies and one Phase IIB study (142 patients).\textsuperscript{45} All patients had normal cardiac function at baseline. The dose range of aldoxorubicin was 175–350 mg/m\textsuperscript{2} administered IV every 3 weeks (equivalent to 130–260 mg/m\textsuperscript{2} doxorubicin per cycle). Prior exposure of up to 225 mg/m\textsuperscript{2} of doxorubicin was allowed. Of the 126 evaluable patients who received 1–21 cycles of aldoxorubicin, no patients developed a decrease in LVEF <50% of their institution’s normal value. Only 14% developed a ≥10% decrease in LVEF, while 21% had an increase in LVEF. When reported, only 3.9% of patients developed a prolonged QTc >500 ms. No patients developed troponin elevation. Although patients received up to 5,439 mg/m\textsuperscript{2} of doxorubicin equivalents, or 12 times the peak cumulative dose of standard doxorubicin, there was no evidence of cardiotoxicity, thereby highlighting its superior cardiac profile.

In the recent Phase III trial, aldoxorubicin (up to 40 cycles) had minimal or no cardiotoxicity compared to doxorubicin.\textsuperscript{40} This protocol was amended to allow aldoxorubicin administration until disease progression or unacceptable toxicities occurred. Interestingly, reduced alopecia was noted with aldoxorubicin and even no evidence of alopecia in a patient receiving up to 20 cycles. Approximately two-thirds of these patients were previously treated with doxorubicin suggesting that resistance may be overcome with a different method of delivery. PEGylated liposomal doxorubicin is more firmly established in the treatment of ovarian cancer, multiple myeloma, and AIDS-related Kaposi sarcoma and also has a relatively favorable toxicity profile compared to conventional doxorubicin.\textsuperscript{46} Although liposomal doxorubicin at 50 mg/m\textsuperscript{2} every 4 weeks was shown to have significantly lower risk of LVEF-defined cardiotoxicity compared to doxorubicin, clinically significant changes in LVEF were seen in 15% of patients receiving a cumulative liposomal doxorubicin dose of >400 mg/m\textsuperscript{2} in a separate pooled analysis.\textsuperscript{46} Furthermore, several single-arm Phase II studies of liposomal doxorubicin in untreated and treatment-refractory advanced STS have shown mixed results on efficacy.\textsuperscript{19,47,48} In a head-to-head Phase II study, liposomal doxorubicin was shown to have equivalent activity to doxorubicin in advanced or metastatic STS.\textsuperscript{19} Taking into consideration the available clinical and safety data to date, aldoxorubicin may represent the superior anthracycline compared to doxorubicin in the treatment of advanced STS. Aldoxorubicin is also a good alternative to standard therapies for the treatment of relapsed or refractory metastatic STS. Aldoxorubicin has
also demonstrated tolerability and activity in combination with other chemotherapy agents in STS; in one study, aldoxorubicin was combined with doxorubicin with no DLTs and additional cardiotoxicity observed.35,36

Future directions of study for this agent will likely involve its incorporation into combination regimens with other chemotherapies, particularly in those with nonoverlapping toxicities to optimize antitumor activity. Notably, there are several trials exploring combination therapy including aldoxorubicin that are ongoing or for which final results are eagerly awaited (NCT01673438, NCT02235701, NCT02235688, NCT02200757). Future trials are warranted exploring aldoxorubicin’s antitumor activity in other tumor types besides STS – several clinical trials are ongoing or for which final results are pending (NCT01580397, NCT02200757, and NCT02014844). Given its superior PFS to doxorubicin, one questions whether aldoxorubicin in combination with olaratumab would provide superior efficacy to the recently FDA-approved combination of doxorubicin and olaratumab in advanced STS.17 Aldoxorubicin provides proof-of-principle that binding an active chemotherapy compound to serum albumin can enhance efficacy without significantly increasing toxicity, and this concept warrants further development with other systemic agents in cancer therapy. Aldoxorubicin can also augment use in anticancer regimens conventionally relying on doxorubicin (such as breast and gynecologic cancers) given its ability to allow higher cumulative doses with minimal cardiotoxicities.

Conclusion

Aldoxorubicin is a tumor-targeting albumin conjugate prodrug of doxorubicin that has shown promising antitumor activity in the first-line and beyond treatment of advanced STS. In the Phase II setting, aldoxorubicin showed superior PFS compared to doxorubicin in the first-line treatment of advanced STS. In a recent Phase III trial, aldoxorubicin demonstrated superior PFS to IC in relapsed or refractory STS. Aldoxorubicin also has a superior safety profile than doxorubicin with respect to cardiotoxicity allowing higher cumulative doses with minimal cardiotoxicity. Taken together, aldoxorubicin may represent the superior anthracycline in the treatment of advanced STS. Aldoxorubicin represents a viable alternative to standard therapies in the treatment of relapsed or refractory STS. Mature and final OS results in the Phase III setting are awaited, and further investigation of aldoxorubicin in combination therapy and in other tumor types is warranted.

Disclosure

The authors report no conflicts of interest in this work.

References


